Research Article

Regulatory Role of miRNAs and IncRNAs in Gout

Jianlong Shu,1 Minhua Chen,2 Chunse Ya,3 Ruixia Yang,4 and Fengzhen Li,1

1Department of Rheumatology, Guangxi International Zhuang Medicine Hospital, Nanning, Guangxi, China 530201
2Department of Ultrasound, Guangxi International Zhuang Medicine Hospital, Nanning, Guangxi, China 530201
3Graduate School, Guangxi University of Chinese Medicine, Nanning, Guangxi, China 530201
4Department of Cardiology, Guangxi International Zhuang Medicine Hospital, Nanning, Qiuyue Road No. 8, Liang Qing District, Nanning, Guangxi Zhuang Autonomous Region, China 530201

Correspondence should be addressed to Fengzhen Li; lifengzhen2005@163.com

Received 20 April 2022; Revised 9 June 2022; Accepted 11 June 2022; Published 29 June 2022

Copyright © 2022 Jianlong Shu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To explore the regulatory functions of ceRNA networks in the nosogenesis of gout and search for potential therapeutic targets.

Methods. We searched the GEO database and downloaded the lncRNA microarray chipset GSE160170. This matrix series was analyzed to yield differentially expressed lncRNAs and mRNAs. Then, the correlations between lncRNAs and miRNAs were obtained by comparing the highly conserved miRNA families. The predicted miRNA-regulating mRNAs were matched to the differentially expressed mRNAs from the chipset analyses to obtain miRNA–mRNA interactions. Next, we used the Cytoscape software to model ceRNA networks and the STRING database to determine their protein–protein interactions. The R software was used to algorithmically screen the functional pathways of key PPI modules in the ceRNA networks. Results. A total of 354 lncRNAs (140 downregulated and 214 upregulated) and 693 mRNAs (399 downregulated and 294 upregulated) were differentially expressed between the gout group and the healthy group. The ceRNA network of differentially expressed lncRNAs contained 86 lncRNAs (35 downregulated and 51 upregulated), 29 miRNAs, and 57 mRNAs. The processes identified in the GO enrichment analysis included gene transcription, RNA polymerase II transcription, and the regulation of cell growth and apoptosis. The pathways identified in the KEGG enrichment analysis included IL-17, TNF, and MAPK signaling. Nine lncRNAs (AC104024, AC084082, AC083843, FAM182A, AC022819, FAM215B, AP000525, TTTY10, and ZNF346-IT1), eleven miRNAs (hsa-miR-1297, hsa-miR-17-5p, hsa-miR-429, hsa-miR-139-5p, hsa-miR-449c-5p, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-23b-3p, hsa-miR-217, hsa-miR-363-3p, and hsa-miR-20b-5p), and nine mRNAs (JUN, CASP2, PMAIP1, FOS, TNFAIP3, MAP3K8, BTG2, NR4A2, and DUSP2) were identified in the exploration of the key modules.

Conclusion. Characterization of ceRNA networks could be a promising approach for better understanding the pathogenesis of gout, with the TTTY10/hsa-miR-139-5p/AP-1 axis likely to be of clinical significance.

1. Introduction

Gout, also known as arthritis rheumatica, is a disease characterized by the precipitation of monosodium urate crystals (MSU) in arthroses. Its prevalence varies worldwide, but the illness onset tends to occur in early adulthood [1]. In China, the incidence of gout ranges from 1% to 3%. Arthritic destruction and multiple organ involvement usually result from disease deterioration due to insufficient treatment [2]. Despite recent studies investigating the correlation of pathogenic physiology with disease progression, the underlying molecular mechanism remains unclear [3]. Our objective is to explore the nosogenesis of gout and discover potential biomarkers and therapeutic targets to support the development of new therapeutic strategies in this field.

Only 2% of human genes are eventually translated into functional proteins, while the rest are transcribed into so-called noncoding RNAs (ncRNAs) [4, 5]. It has been shown that these ncRNAs could regulate the expression of other genes. ncRNAs are classified as microRNAs (miRNAs) or long noncoding RNAs (lncRNAs) depending on their lengths. To explain the mechanisms by which ncRNAs modulate disease progression, it has been hypothesized that competing endogenous RNAs (ceRNAs) could emulate miRNAs,
bind to a messenger RNA (mRNA), and prevent its translation [6, 7]. The miRNA response elements (MREs) of lncRNAs can also bind to mRNAs and compete with miRNAs [8]. RNA molecules transcribed by RNA polymerase II are longer than two hundred nucleotides and lack a reading frame are considered lncRNAs [9]. In gout, these molecules facilitate the degradation of the extracellular matrix in cartilage cells and transduce inflammatory signals. They can also mediate disease severity by regulating the invasion pathways of fibroblast-like synoviocytes [10, 11]. miRNAs regulate gene expression via subtle and intricate mechanisms. They have been shown to initiate inflammation in acute gout as essential constituents of MSU-induced inflammatory pathways [12, 13], with lncRNAs playing analogous roles in this process [3]. Although the involvement of ceRNAs in various disorders has been verified, few reports have demonstrated their roles in gout. Thus, this study was conceived to further investigate the interactions of three RNA subtypes (lncRNA, miRNA, and mRNA) in regulating gene transcription in gout.

2. Methods

2.1. Search Strategy. We obtained the relevant lncRNA microarray and expression data from the NCBI GEO database (https://www.ncbi.nlm.nih.gov/geo/) dating from January 2010 to March 2021 via searching using the following keywords: “Gout”, “lncRNA”, and “Human”.

2.2. Database Downloads. Based on the above results, the GSE160170 dataset (platform GPL21827, probe Agilent_079487, Arraystar human microarray V4; https://www.ncbi.nlm.nih.gov/geo/) was downloaded from the GEO database, including its matrix series and platform files. This chipset consisted of analyses of twelve peripheral blood samples, among which half were from healthy subjects and half from gout patients.

2.3. Reannotation and Comparison. The PERL software (Edition 5.30.0) was utilized to reassign the probe nucleotide sequences from the GEO platform into FASTA format. Next, the nucleotide sequences of all human transcribed sequences were downloaded from the GENCODE platform (https://www.gencodegenes.org/). They were compared with the probe sequences to yield probe files with corresponding gene labels.

2.4. Annotation of Matrix Series. To distinguish mRNAs from lncRNAs, the PERL software was applied to compare the matrix series to the probe files to match the probe IDs in the matrix series with the corresponding gene labels. Then, we used the downloaded human gene annotation file (.gtf file) to acquire the additional gene data in the software.

2.5. Expression Variation Analysis. We used the R software (Edition 4.0.4, “limma” mode) to analyze the differentially expressed genes in the matrix series. Using the setting logFC (log 2 – fold change) > 1 or -1 along with adjusted P value < 0.05 as the prerequisite parameters, a volcano plot was mapped following the differential lncRNAs and mRNAs from the chipset. The HETML software was then used to generate dendrograms and heat maps of hierarchical clustering. In the plots, LogFC > 1 and LogFC < 1 indicated the upregulation and downregulation of this particular differential lncRNA in gout patients, respectively.

2.6. Prediction of miRNA Binding to lncRNAs. We downloaded the conserved miRNA family files from the miRcode platform (http://www.mircode.org/). Then, the PERL software was used to verify the interactions between differentially expressed lncRNAs and miRNAs to predict their connections.

2.7. Prediction of mRNAs Regulated by miRNAs. The predictions of regulatory relationships between mRNA and miRNAs were made based on the miRDB database (http://mirdb.org/), the miRTarBase database (http://miirtarbase.mbc.nctu.edu.tw/php/index.php), and the TargetScan database (http://www.targetscan.org/vert_72/). Only those pairs predicted by all three databases were retained for further study. The PERL software validated the sequence identity when the prediction results were compared with the differential mRNAs from the chipset and thus yielded a set of miRNA–mRNA associations.

2.8. Construction of ceRNA Networks. We modeled coexpressed lncRNA–miRNA–mRNA triads according to the ceRNA concept. The ceRNA networks of upregulated and downregulated differentially expressed lncRNAs were plotted by Cytoscape software (Edition 3.8.2). The connection between the two frame points represented a regulatory relationship.

2.9. Construction and Analysis of the Protein–Protein Interaction (PPI) Network. We enacted a confidence interval > 0.9 as the parameter to screen protein components in the PPI network and evaluated their interactions by searching the STRING database (Edition 11.0, https://string-db.org/). The Cytoscape software delineated the network plot after loading in the STRING database. Next, using the setting degree cutoff = 2, score cutoff = 0.2, k – core = 2, and max.depth = 100 as the parameters, we visualized the essential lncRNA–miRNA–mRNA subnetworks by using the algorithms in the MCODE plugin. The GO and KEGG pathway annotations of every key lncRNA were further identified by assessing the original and subnetwork mRNAs in the ceRNA networks.

2.10. GO and KEGG Enrichment Analysis. To determine the functions of the key PPI modules, the DAVID database was filtered for GO enrichment analysis. The gene data were then exported into Excel, and the GO enrichment analysis plot was made by GraphPad Prism (Edition 9.0.2). We also used the R software to perform KEGG enrichment analysis and assay the relevant pathways. P value < 0.05 represented statistical significance.

2.11. Exploration of the Key ceRNA Networks. The analysis of miRNAs competitively bound to lncRNAs and mRNAs was performed by exploring the KEGG-enriched mRNAs in the
ceRNA networks. The key ceRNA network was generated from the above results in the Cytoscape software to search for pathways regulating crucial genes in the KEGG enrichment analysis plot.

3. Results

3.1. Differentially Expressed IncRNAs and mRNAs. A total of 354 differentially expressed IncRNAs were identified by comparing the gout group and the healthy group by setting \(|\log FC| > 1\) and adjusted \(P\) value < 0.05 as the parameters. A total of 140 were downregulated, whereas the rest were upregulated. A total of 693 mRNAs were identified via similar comparisons, among which 399 were downregulated and 294 were upregulated. Figure 1 shows the volcano plot of hierarchical clustering of differentially expressed IncRNAs. Figure 2 shows the dendrogram and heat map of hierarchical clustering of differentially expressed IncRNAs, and Figure 3 shows the dendrogram and heat map of hierarchical clustering of differentially expressed mRNAs.

3.2. The ceRNA Network of Differentially Expressed IncRNAs. There were 86 IncRNAs in the ceRNA network (35 were downregulated, 51 were upregulated). Twenty-nine miRNAs were screened out by the predictions of all three databases (miRDB, miRTarBase, and TargetScan). The mRNAs regulated by those miRNAs were further compared with those from the chipset data, and we obtained 57 common mRNAs. Figures 4 and 5 show the ceRNA networks of upregulated and downregulated differentially expressed IncRNAs. Table 1 lists the upregulated and downregulated mRNAs in the ceRNA network.

3.3. Analyses of the PPI Network and Key Modes. Using the setting confidence coefficient > 0.4, 33 protein–protein interactions involving 57 proteins were obtained. Two key modules of protein–protein interactions were identified by the Cytoscape MCODE mode. Module 1 consisted of JUN, CASP2, and PMAIP1. Module 2 consisted of FOS, TNFAIP3, MAP3K8, BTG2, NR4A2, and DUSP2 (Figure 6).

3.4. GO Enrichment Analysis. Given a \(P\) value < 0.05, we identified 57 mRNAs for GO enrichment analysis. These subjects included numerous cellular components, biological process, and molecular function terms. The enriched biological process terms included DNA transcription, cell proliferation, RNA polymerase II promoter transcription, cell program death, lipopolysaccharide metabolism, cell matura-

3.5. KEGG Enrichment Analysis. We set the \(P\) value < 0.05 to analyze the pathways involving TNF, IL-17, and MAPK signaling via the “Colorspace,” “Stringi,” and “BiocManager” modes in R software. The outcomes are shown in Figure 8.

3.6. Key ceRNA Network. The key ceRNA network was filtered to identify the key modules in which IncRNAs are bound to miRNAs in competition with the enriched mRNAs. We discovered that the extents of up- and down-regulation were identical in the same groups of mRNAs and miRNAs. The eleven miRNAs identified to be under the influences of their respective IncRNAs were as follows: hsa-miR-1297, hsa-miR-17-5p, hsa-miR-429, hsa-miR-139-5p, hsa-miR-449c-5p, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-23b-3p, hsa-miR-217, hsa-miR-363-3p, and hsa-miR-20b-5p (Figures 9 and 10).

3.7. Key Regulatory Network. Considering the identification of the TNF and IL-17 signaling pathways in the KEGG enrichment analysis, the FOS and JUN mRNA components were likely to act as the principal factors in the pathophysiology of gout (https://www.kegg.jp/pathway/map04657, https://www.kegg.jp/pathway/map04668). They bounded to hsa-miR-139-5P in competition with IncRNAs including AC104024, AC084082, AC083843, FAM182A, AC022819, FAM215B, AP000525, TTTY10, and ZNF346-IT1. Among them, AC104024, AC084082, AC083843, and FAM182A were downregulated, and AC022819, FAM215B, TTTY10, and ZNF346-IT1 were upregulated (Table 2). We constructed the representative ceRNA signaling pathways in cellular responses to hormones, cytokines and mechanical stimuli, signal conduction of SMAD protein, DNA damage signaling, and transforming growth factor (TGF) receptor signaling pathways. These modules were responsible for regulating the production of nuclear and cytoplasmic materials and facilitating protein and DNA associations, the activities of protein heterodimers and transcription factors, the binding of sequence-specific DNAs and R-SMADs, and other processes (Figure 7).
Figure 2: Dendrogram and heat map of hierarchical clustering of differentially expressed IncRNAs. Note: the x-axis shows the sample names of the chipsets. The y-axis is labeled with the names of IncRNAs. Red represents a high level of relative expression; green represents a low relative expression level. Black indicates nonsignificant differences in relative expression. Blue represents peripheral blood samples from healthy subjects; pink represents peripheral blood samples from gout subjects. The branches on the y-axis represent the clustering of various IncRNAs. The twelve IncRNA samples were clustered into three categories sharing similar differential expression patterns.
4. Discussion

Gout, a type of arthritis caused by the precipitation of MSU crystals in joints, can result in acute inflammation and damage to adjacent tissues. Its representative features are the rapid onset of sharp pain and self-limiting symptoms (lasting 3-14 days) [14]. Moreover, its incidence is increasing in developed countries [15]. Common comorbidities include cardiovascular diseases, nephrolithiasis, obesity, and diabetes. In addition to the physical pain it causes for patients,
medical treatments for gout are often unaffordable, and this disease impacts the productivity of society as a whole [16]. The scientific consensus is that the physiological basis of gout involves the activation of the NF-KB pathways by Toll receptors after MSU crystals are recognized by macrophages [17]. This response releases IL-1β from inflammasomes via the NLRP3 signaling to generate rheumatic manifestations [18]. Inflammatory signals recruit neutrophils to capture MSU by exocytosing extracellular traps; then, macrophages engulf apoptotic neutrophils to relieve inflammation activities. Many AP-1 binding sites have been reported to exist in the promoters of inflammatory genes in gout, such as Act1, TRAF6, NF-κB, AP-1, FOS, JUN, IL-1β, and COX-2, were mainly involved in the IL-17 and TNF signaling pathways. The FOS and JUN genes were differentially expressed after matching with the mRNAs in the key ceRNA network. Nine IncRNAs that could bind competitively to hsa-miR-139-5P, the potential miRNA target to which the FOS and JUNE genes are also bound, were identified. Among these IncRNAs, AC104024, AC084082, AC083843, and FAM182A were downregulated, whereas AC022819, FAM215B, AP000525, TTTY10, and ZNF346-IT1 were upregulated. Intriguingly, both upregulation and downregulation were observed in AC083843 and FAM182A. Act1, one of the downstream components of the IL-17 pathway, was shown to stabilize mRNA expression and mediate inflammatory signal conduction as an adaptor of the IL-17 receptor [28]. TRAF6, another downstream component, acts as the receptor kinase of IL-17 to trigger signal transmission through the pathway by inducing NF-κB to activate inflammatory factors and cytokines (NF-κB and AP-1 are mutually dependent). AP-1 exhibits paradoxical properties in the regulation of gene transcription. Its subunits include c-Fos, c-Jun, Jun B, and Jun D, of which c-Fos and c-Jun shared the most extensive transcription initiation activities. Many AP-1 binding sites have been reported to exist in the promoters of inflammatory factors (IL-1β and TNF-α), growth factors, and matrix metalloproteinase (MMP2 and MMP9) [29–31]. They alternate between proinflammatory and phagocytic processes [29]. Nevertheless, some AP-1 downstream targets inhibit inflammatory responses, such as the Th2 cytokines IL-4, IL-5, and IL-13, whose expression is subject to regulation by AP-1 through its binding to the corresponding gene promoters [32]. In the IL-17 signaling pathway, the subtypes IL-17A, IL-17B, and...
IL-17C, and IL-17F are proinflammatory, whereas IL-17E acts as an anti-inflammatory agent. COX-2 is another gene under the regulation of AP-1. Its localization on the nuclear surface allows convenient entrance into the nucleus and direct influence on gene expression. The promoter of the COX-2 gene contains multiple TF binding sites, including those for AP-1 and NF-KB [33]. PGE2, one of the essential products of COX-2, enhances the local inflammatory response and recruits circulating leukocytes to secrete cytokines [34].

Several studies have reported on the activities of miR-139-5p, an miRNA that binds to the JUN and FOS genes [35]. Analysis using the DIANA TOOLS software (http://diana.imis.athena-innovation.gr/DianaTools/index.php) confirmed the binding sites for miR-139-5p within JUN and TRAF6. Recent publications have indicated that
miR-139-5p decreases the plasma concentrations of IL-1β and TNF-α by adjusting TRAF6 to alter the inflammatory and oxidizing responses of macrophages. Furthermore, miR-139-5p was shown to promote the activities of T cells by targeting c-Jun and c-Fos [36]. Therefore, we speculated that miR-139-5p might be critically important in the nosogenesis of gout.

Table 2: Parameters of up- and downregulated lncRNAs.

| IncRNA    | logFC    | AveExpr | t       | P value   | Adjusted P value |
|-----------|----------|---------|---------|-----------|------------------|
| TTTY10    | 1.182591 | 4.3677  | 5.798418| 0.000112  | 0.001618         |
| AC022819  | 1.109496 | 3.124482| 10.29479| 4.81E-07  | 4.05E-05         |
| FAM215B   | 1.071295 | 4.445856| 4.068199| 0.001797  | 0.011922         |
| ZNF346-IT1| 1.042113 | 6.191628| 8.010408| 5.82E-06  | 0.000217         |
| AP000525  | 1.02872  | 9.056032| 3.880768| 0.002485  | 0.01497          |
| AC084082  | -1.0971  | 3.392878| -4.0296 | 0.00192   | 0.012499         |
| AC083843  | -1.12263 | 6.323656| -4.40739| 0.00101   | 0.007905         |
| AC104024  | -1.22902 | 4.098741| -5.29094| 0.000242  | 0.002786         |
| FAM182A   | -1.3358  | 3.573437| -4.38903| 0.001042  | 0.008078         |

Note: logFC > 1 indicates upregulation, logFC < −1 indicates downregulation.
Among the lncRNAs competing with miR-139-5p, FAM182A had the most extensive downregulation, while TTTY10 was the most upregulated. Although the functions of lncRNAs other than TTTY10 are yet to be explored, nine other lncRNA subjects were hypothesized to produce similar effects. TTTY10 participates in cell attachment, transcription, signal conduction, growth, and differentiation via the FoxO1 gene [37]. It is a crucial transcription factor that shares identical regulatory functions with NF-KB and AP-1. FoxO1 can also relieve inflammation by inhibiting the NF-KB-, FoxO1-, and AP-1-related pathways [38, 39]. Thus, we concluded that TTTY10 was of great importance in executing the inflammatory responses of immune cells.

Due to the involvement of IL-17 in immune regulatory functions, the effects of IL-17 inhibitors have been investigated in autoimmune diseases. The US Food and Drug Administration (FDA) has approved the IL-17 inhibiting monoclonal antibody secukinumab (trade name: Cosentyx) to treat severe plaque psoriasis [40]. Further, the anti-IL-23 antibody ustekinumab was shown to effectively treat moderate-to-severe psoriasis by indirectly reducing IL-17 [41]. Presently, TNF-α inhibitors such as infliximab, adalimumab, etanercept, certolizumab pegol, and golimumab are being clinically used to treat inflammatory diseases [42–44]. In a case report by Zhang et al., the researchers showed that the TNF-α antagonist etanercept, given at 25 mg subcutaneous injection two times a week, could significantly relieve joint pain one day after treatment and completely relieve it after five days of treatment. Further, after 2 weeks, the levels of C-reactive protein (CRP) and blood routine examination returned to normal [44]. In a genome-wide study by White et al., the authors showed the promising effects of certolizumab pegol in moderate to severe rheumatoid arthritis [45].

Lastly, although lncRNAs may participate in the progression of arthritis by competing with miRNAs, few studies have reported the existence of binding sites between the aforementioned lncRNAs and miR-139-5p; therefore, no sufficient evidence supports the hypothesis that lncRNAs regulate cytokine secretion via miR-139-5p. We designed this study in the hope of adding new knowledge to the currently available options for gout therapy. The power of our research, however, had some limitations given the predictive nature of bioinformatics analyses and several clinical trials. No systemic proof has been found beyond the existence of these lncRNA–miRNA–mRNA networks. In future work, we expect to verify the differential expression of lncRNAs in patients and healthy subjects in the clinic. The principle will be to study the regulatory mechanisms of lncRNAs binding to miR-139-5p in competition with the JUN and FOS genes. The mechanisms underlying the interactions between the subtypes of c-fos and c-jun, as well as how lncRNAs and miR-139-5p restrict their transcription, require further detailed characterization.

In conclusion, the principle of targeting miRNAs and lncRNAs in gout therapy urges more prospective explorations in the clinic.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.
Conflicts of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Authors’ Contributions

Jianlong Shu, Minhua Chen, and Chunse Ya contributed equally to this work.

Acknowledgments

We appreciate the support provided by the technology department of Guangxi International Zhuang Medicine Hospital scientific research start-up fund project (GZ2021RC003). The following funds sponsored this study: “Guangxi Innovation-Driven Development Funding (AA17202034), “The Young Foundation of State Administration of Traditional Chinese Medicine of Guangxi Zhuang Autonomous Region (GXYZ20210173), “The Young Foundation of First-rate Students in Guangxi University of Chinese Medicine (2019XK046),” and “The Innovation Program of Guangxi International Zhuang Medicine Hospital (2019011).”

References

[1] R. Day, A. Nguyen, G. Graham, E. Aung, M. Coleshill, and S. Stocker, “Better outcomes for patients with gout,” Inflammopharmacology, vol. 26, no. 5, pp. 1395–1400, 2020.
[2] P. Yang, Z. Chen, Y. T. Chen et al., “Use of the gout impact scale to evaluate quality of life in Chinese subjects with gout: a cross-sectional study,” Medical Science Monitor, vol. 26, article e925593, 2020.
[3] Y. T. Xu, Y. R. Leng, M. M. Liu et al., “MicroRNA and long noncoding RNA involvement in gout and prospects for treatment,” International Immunopharmacology, vol. 87, p. 106842, 2020.
[4] U. Gezer, E. Ozgur, M. Cetinkaya, M. Isin, and N. Dalay, “Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes,” Cell Biology International, vol. 38, no. 9, pp. 1076–1079, 2014.
[5] H. Jiang, R. Ma, S. Zou, Y. Wang, Z. Li, and W. Li, “Reconstruction and analysis of the lncRNA-miRNA–mRNA network based on competitive endogenous RNA reveal functional lncRNAs in rheumatoid arthritis,” Molecular Biosystems, vol. 13, no. 6, pp. 1182–1192, 2017.
[6] L. Salmena, L. Poliseno, Y. Tay, L. Kats, and P. P. Pandolfi, “A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?,” Cell, vol. 146, no. 3, pp. 353–358, 2011.
[7] Y. Tay, J. Rinn, and P. P. Pandolfi, “The multilayered complexity of ceRNA crosstalk and competition,” Nature, vol. 505, no. 7483, pp. 344–352, 2014.
[8] D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009.
[9] C. P. Ponting, P. L. Oliver, and W. Reik, “Evolution and functions of long noncoding RNAs,” Cell, vol. 136, no. 4, pp. 629–641, 2009.
[10] Q. Liu, X. Zhang, L. Dai et al., “Long noncoding RNA related to cartilage injury promotes chondrocyte extracellular matrix degradation in osteoarthritis,” Arthritis & Rheumatology, vol. 66, no. 4, pp. 969–978, 2014.
[11] C. L. Chew, S. A. Conos, B. Unal, and V. Tergaonkar, “Noncoding RNAs: master regulators of inflammatory signaling,” Trends in Molecular Medicine, vol. 24, no. 1, pp. 66–84, 2018.
[12] P. Galozzi, S. Bindoli, A. Doria, F. Oliviero, and P. Sfriso, “Autoinflammatory features in gouty arthritis,” Journal of Clinical Medicine, vol. 10, no. 9, p. 1880, 2021.
[13] P. Papanagnostou, T. Stivarou, and M. Tsironi, “The role of miRNAs in common inflammatory arthropathies: osteoarthritis and gouty arthritis,” Biomolecules, vol. 6, no. 4, p. 44, 2016.
[14] T. Neogi, “Gout,” The New England Journal of Medicine, vol. 364, no. 5, pp. 443–452, 2011.
[15] C. F. Kuo, M. J. Grainge, W. Zhang, and M. Doherty, “Global epidemiology of gout: prevalence, incidence and risk factors,” Nature Reviews Rheumatology, vol. 11, no. 11, pp. 649–662, 2015.
[16] L. K. Stamp and N. Dalbeth, “Prevention and treatment of gout,” Nature Reviews Rheumatology, vol. 15, no. 2, pp. 68–70, 2019.
[17] A. K. So and F. Martinon, “Inflammation in gout: mechanisms and therapeutic targets,” Nature Reviews Rheumatology, vol. 13, no. 11, pp. 639–647, 2017.
[18] P. Sil, H. Wicklum, C. Surell, and B. Rada, “Macrophage-derived IL-1β enhances monosodium urate crystal-triggered NET formation,” Inflammation Research, vol. 66, no. 3, pp. 227–237, 2017.
[19] F. Apel, A. Zychlinsky, and E. F. Kenny, “The role of neutrophil extracellular traps in rheumatic diseases,” Nature Reviews Rheumatology, vol. 14, no. 8, pp. 467–475, 2018.
[20] J. J. Chan and Y. Tay, “Noncoding RNA:RNA regulatory networks in cancer,” International Journal of Molecular Sciences, vol. 19, no. 5, p. 1310, 2018.
[21] R. W. Yao, Y. Wang, and L. L. Chen, “Cellular functions of long noncoding RNAs,” Nature Cell Biology, vol. 21, no. 5, pp. 542–551, 2019.
[22] Q. W. Li, W. Lei, C. Chen, and W. Guo, “Recent advances of long noncoding RNAs involved in the development of multiple sclerosis,” Chinese Journal of Natural Medicines, vol. 18, no. 1, pp. 36–46, 2020.
[23] Y. T. Tan, J. F. Lin, T. Li, J. J. Li, R. H. Xu, and H. Q. Ju, “lncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer,” Cancer Communications, vol. 41, no. 2, pp. 109–120, 2021.
[24] Y. Wang, D. Xu, B. Wang, and X. Hou, “Could microRNAs be regulators of gout pathogenesis?,” Cellular Physiology and Biochemistry, vol. 36, no. 5, pp. 1679–1687, 2015.
[25] Q. B. Zhang, Y. F. Qing, C. C. Yin et al., “Mice with miR-146a deficiency develop severe gouty arthritis via dysregulation of TRAF 6, IRAK 1 and NALF3 inflammasome,” Arthritis Research & Therapy, vol. 20, no. 1, p. 45, 2018.
[26] M. K. Atianand, W. Hu, A. T. Satpathy et al., “A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation,” Cell, vol. 165, no. 7, pp. 1672–1685, 2016.
[27] Y. G. Chen, A. T. Satpathy, and H. Y. Chang, “Gene regulation in the immune system by long noncoding RNAs,” Nature Immunology, vol. 18, no. 9, pp. 962–972, 2017.
[28] T. Herjan, L. Hong, J. Bubenik et al., “IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-
17 inflammatory signaling,” *Nature Immunology*, vol. 19, no. 4, pp. 354–365, 2018.

[29] A. K. Hubbard and R. Rothlein, “Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades,” *Free Radical Biology & Medicine*, vol. 28, no. 9, pp. 1379–1386, 2000.

[30] S. Shiozawa and K. Tsumiyama, “Pathogenesis of rheumatoid arthritis and c-Fos/AP-1,” *Cell Cycle*, vol. 8, no. 10, pp. 1539–1543, 2009.

[31] E. F. Wagner, “Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun),” *Annals of the Rheumatic Diseases*, vol. 69, Suppl 1, pp. i86–i88, 2010.

[32] A. Gungl, V. Biasin, J. Wilhelm, A. Olschewski, G. Kwapiszewka, and L. M. Marsh, “Fra2 overexpression in mice leads to non-allergic asthma development in an IL-13 dependent manner,” *Frontiers in Immunology*, vol. 9, p. 2018, 2018.

[33] N. Q. Do, S. Zheng, B. Park et al., “Camu-camu fruit extract inhibits oxidative stress and inflammatory responses by regulating NFAT and Nrf2 signaling pathways in high glucose-induced human keratinocytes,” *Molecules*, vol. 26, no. 11, p. 3174, 2021.

[34] Y. Zhang, Y. Zhou, S. Chen et al., “Macrophage migration inhibitory factor facilitates prostaglandin E2 production of astrocytes to tune inflammatory milieu following spinal cord injury,” *Journal of Neuroinflammation*, vol. 16, no. 1, p. 85, 2019.

[35] X. Xu, T. Ye, Y. Wang et al., “MicroRNA-139-5p inhibits inflammatory and oxidative stress responses of Salmonella-infected macrophages through modulating TRAF6,” *Pathogens and Disease*, vol. 79, no. 4, 2021.

[36] I. Okoye, L. Xu, O. Oyegbami et al., “Plasma extracellular vesicles enhance HIV-1 infection of activated CD4+ T cells and promote the activation of latently infected J-Lat10.6 cells via miR-139-5p transfer,” *Frontiers in Immunology*, vol. 12, p. 697604, 2021.

[37] L. Wu, H. Li, C. Y. Jia et al., “MicroRNA-223 regulates FOXO1 expression and cell proliferation,” *FEBS Letters*, vol. 586, no. 7, pp. 1038–1043, 2012.

[38] C. C. Yang, C. C. Lin, L. D. Hsiao, and C. M. Yang, “Galangin inhibits thrombin-induced MMP-9 expression in SK-N-SH cells via protein kinase-dependent NF-κB phosphorylation,” *International Journal of Molecular Sciences*, vol. 19, no. 12, p. 4084, 2018.

[39] C. C. Yang, L. D. Hsiao, and C. M. Yang, “Galangin inhibits LPS-induced MMP-9 expression via suppressing protein kinase-dependent AP-1 and FoxO1 activation in rat brain astrocytes,” *Journal of Inflammation Research*, vol. 13, pp. 945–960, 2020.

[40] K. M. Darch, T. L. Holland, and L. J. Spelman, “Secukinumab-induced inflammatory bowel disease in a patient treated for chronic plaque psoriasis and psoriatic arthritis: a case report and review of the role of novel biologic agents targeting the p19 subunit of IL-23,” *Case Reports in Medicine*, vol. 2020, Article ID 9404505, 6 pages, 2020.

[41] C. L. Leonardi, A. B. Kimball, K. A. Papp et al., “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1),” *Lancet*, vol. 371, no. 9625, pp. 1665–1674, 2008.

[42] C. Selmi, E. Generali, M. Massarotti, G. Bianchi, and C. A. Scire, “New treatments for inflammatory rheumatic disease,” *Immunologic Research*, vol. 60, no. 2-3, pp. 277–288, 2014.

[43] A. Sonoda, R. Ogawa, K. Mizukami et al., “Marked improvement in gastric involvement in Behçet’s disease with adalimumab treatment,” *The Turkish Journal of Gastroenterology*, vol. 28, no. 5, pp. 405–407, 2017.

[44] Y. Zhang, R. Pan, Y. Xu, and Y. Zhao, “Treatment of refractory gout with TNF-α antagonist etanercept combined with febuxostat,” *Annals of Palliative Medicine*, vol. 9, no. 6, pp. 4332–4338, 2020.

[45] I. R. White, S. E. Kleinstein, C. Praet et al., “A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population,” *PLoS One*, vol. 17, no. 4, article e0261165, 2022.